To provide for increased research and initiatives related to bleeding disorders in underserved populations, and for other purposes.

Overview

HR 8794 (119th Congress) aims to enhance research and initiatives related to bleeding disorders, with a particular focus on underserved populations. The bill seeks to expand federal engagement, funding opportunities, and programmatic efforts to improve diagnosis, treatment, and awareness of bleeding disorders across communities that traditionally face access and equity barriers.

Main purpose and intent

• Improve understanding and management of bleeding disorders (e.g., hemophilia, von Willebrand disease, and related conditions).
• Expand research efforts to identify disparities in prevalence, access to care, and outcomes among underserved populations.
• Promote targeted initiatives to reduce barriers to diagnosis, treatment, and comprehensive care for individuals with bleeding disorders.

Key provisions and changes

Note: The bill text is not provided here, so the following reflects common elements typically associated with a bill of this scope and the information available from the summary and action history. If enacted, the bill could include:

• Establishment or expansion of federal research programs dedicated to bleeding disorders, with a emphasis on underserved communities.
• Allocation of funding for clinical and translational research to improve diagnostics, treatment options (including prophylaxis and innovative therapies), and patient-reported outcomes.
• Development of outreach and education initiatives to raise awareness among patients, families, healthcare providers, and community organizations in underserved areas.
• Support for data collection, surveillance, and reporting to better track prevalence, treatment access, and health outcomes related to bleeding disorders.
• Enhancement of grants or cooperative agreements to academic medical centers, nonprofit organizations, and health systems that specialize in bleeding disorders.
• Provisions to encourage collaboration with other federal programs (e.g., NIH, CDC, HRSA) and with patient advocacy groups.

Who or what would be affected

• Individuals living with bleeding disorders, especially those in underserved or under-resourced communities.
• Healthcare providers and hospitals that diagnose and treat bleeding disorders.
• Researchers and academic institutions conducting studies on bleeding disorders and related health disparities.
• Community-based organizations and patient advocacy groups engaged in hematology, rare diseases, and minority health initiatives.
• Federal agencies involved in health research and public health surveillance (potentially NIH, CDC, HRSA).

Procedural and timeline aspects

• Status: Introduced in the House and referred to the House Committee on Energy and Commerce on May 13, 2026.
• Next steps: Within the committee, the bill could undergo hearings, markups, and potential amendments. If advanced, it would proceed to the full House for consideration, then to the Senate (and potential conference if there are differences).
• Sponsorship: Primary and co-sponsors include Rep. (listed as sponsors) with noted co-sponsors Sarah McBride, Joe Wilson, and Julie Johnson, indicating bipartisan interest.

Potential impact and considerations

• Increased federal funding and attention to bleeding disorders in underserved populations could improve access to diagnostics, specialty care, and modern therapies.
• Improved data collection may lead to better policy decisions and allocation of resources.
• The effectiveness will depend on final text, including funding levels, specific programs, reporting requirements, and oversight mechanisms.

If you have access to the full bill text, I can refine this summary with exact sections, dollar amounts, program names, and timeline details.